Consists of Betamethasone sodium phosphate, Betamethasone valerate
What is Betamethasone sodium phosphate?
Betamethasone sodium phosphate sodium phosphate and Betamethasone sodium phosphate acetate combination injection provides relief for inflamed areas of the body. It is used to treat a number of different conditions, such as inflammation (swelling), severe allergies, adrenal problems, arthritis, lung or breathing problems, blood or bone marrow problems, eye or vision problems, lupus, serious skin conditions, kidney problems, ulcerative colitis, and flare-ups of multiple sclerosis. Betamethasone sodium phosphate sodium phosphate and Betamethasone sodium phosphate acetate combination is a corticosteroid (cortisone-like medicine or steroid). It works on the immune system to help relieve swelling, redness, itching, and allergic reactions.
Betamethasone sodium phosphate sodium phosphate and Betamethasone sodium phosphate acetate is to be given only by or under the direct supervision of your doctor.
Betamethasone sodium phosphate indications
Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions.
Dermatologic Diseases
Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
Endocrine Disorders
Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis.
Hematologic Disorders
Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous
Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy.
Neoplastic Diseases
For palliative management of leukemias and lymphomas.
Nervous System
Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases
Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases
To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
Respiratory Diseases
Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
The intra-articular or soft tissue administration of Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
The intralesional administration of Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum.
Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia
How should I use Betamethasone sodium phosphate?
Use Betamethasone sodium phosphate as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Betamethasone sodium phosphate is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Betamethasone sodium phosphate at home, a health care provider will teach you how to use it. Be sure you understand how to use Betamethasone sodium phosphate. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Do not use Betamethasone sodium phosphate if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
- If you miss a dose of Betamethasone sodium phosphate, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Betamethasone sodium phosphate.
Uses of Betamethasone sodium phosphate in details
Betamethasone sodium phosphate is used to treat allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, and bronchial asthma
Topical preparations of Betamethasone sodium phosphate are used to treat skin problems like eczema (a type of itchy skin rash), atopic dermatitis (inflammation of skin) and psoriasis of the scalp, hands and feet.
Betamethasone sodium phosphate description
A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes Betamethasone sodium phosphate particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
Betamethasone sodium phosphate dosage
1-2 drops every 4-6 hrs until sign of improvement are apparent.
Betamethasone sodium phosphate interactions
See also:
What other drugs will affect Betamethasone sodium phosphate?
Concurrent use of Phenobarbital, Phenytoin, rifampin or ephedrine may enhance the metabolism of corticosteroids, reducing their therapeutic effects.
Patients receiving both a corticosteroid an estrogen should be observed for excessive corticosteroid effects.
Concurrent use of corticosteroids with potassium-depleting diuretics may enhance
Hypokalemia with cardiac glycosides may enhance the possibility of arrhythmias or digitalis toxicity associated with hypokalemia. Corticosteroids may enhance the potassium depletion caused by amphotericin B. In all patients taking any of these drug therapy combinations, serum electrolyte determinations, particularly potassium levels should be monitored closely.
Concurrent use of corticosteroids with coumarin-type anticoagulants may increase or decrease the anticoagulant effects possibly requiring adjustment in dosage.
Combined effects of non-steroidal anti-inflammatory drugs or alcohol with glucocorticosteroids may result in an increased occurrence or increased severity of gastrointestinal ulceration.
Corticosteroids may decrease blood salicylate concentrations. Acetylsalicylic acid should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
Dosage adjustments of an antidiabetic drug may be necessary when corticosteroids are given to diabetics.
Concomitant glucocorticosteroid therapy may inhibit the response to somatotropin.
Laboratory test interactions: corticosteroids may affect the nitroblue tetrazolium test for bacterial infection and produce false negative results.
Betamethasone sodium phosphate side effects
See also:
What are the possible side effects of Betamethasone sodium phosphate?
Allergic Reactions
Anaphylactoid reaction, anaphylaxis, angioedema.
Cardiovascular
Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis.
Dermatologic
Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria.
Endocrine
Decreased carbohydrate and glucose tolerance, development of cushingoid state, glucosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients.
Fluid and Electrolyte Disturbances
Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention.
Gastrointestinal
Abdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis.
Metabolic
Negative nitrogen balance due to protein catabolism.
Musculoskeletal
Aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intralesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, postinjection flare (following intra-articular use), steroid myopathy, tendon rupture, vertebral compression fractures.
Neurologic/Psychiatric
Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Arachnoiditis, meningitis, paraparesis/paraplegia, and sensory disturbances have occurred after intrathecal administration.
Ophthalmic
Exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts, rare instances of blindness associated with periocular injections.
Other
Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain.
Betamethasone sodium phosphate contraindications
See also:
What is the most important information I should know about Betamethasone sodium phosphate?
Injectable Suspension is contraindicated in patients who are hypersensitive to any components of this product.
Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.
What is Betamethasone valerate?
Reducing itching, redness, and swelling associated with skin conditions of the scalp. It may also be used for other conditions as determined by your doctor.
Betamethasone valerate valerate foam is a topical corticosteroid. It works by depressing the formation, release, and activity of different cells and chemicals that cause swelling, redness, and itching.
Betamethasone valerate indications
Betamethasone valerate Valerate Foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
How should I use Betamethasone valerate?
Use Betamethasone valerate valerate foam as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- An extra patient leaflet is available with Betamethasone valerate valerate foam. Talk to your pharmacist if you have questions about this information.
- Before using for the first time, break the tiny plastic piece at the base of the can's rim by gently pushing back (away from the piece) on the nozzle.
- Turn the can upside down and dispense a small amount of Betamethasone valerate valerate foam onto a clean saucer or other cool, clean surface. Do not dispense directly onto your hands because the foam will begin to melt immediately upon contact with warm skin.
- Pick up small amounts of foam with fingers and gently massage into the affected area until foam disappears. Repeat until entire affected area has been treated. Use only enough to cover the entire affected area.
- When applying, move the hair away so that the foam can be applied directly to the affected skin.
- Wash your hands immediately after using Betamethasone valerate valerate foam.
- Throw away any unused medicine that has been dispensed from the container.
- Do not wash or rinse the treated areas immediately after applying Betamethasone valerate valerate foam.
- Do not cover the treating area with bandages, wrappings, or other dressings unless advised to do so by your health care provider.
- If you miss a dose of Betamethasone valerate valerate foam, apply it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Betamethasone valerate valerate foam.
Uses of Betamethasone valerate in details
This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Betamethasone valerate reduces the swelling, itching, and redness that can occur in these types of conditions. This medication is a medium-strength corticosteroid.
How to use Betamethasone valerate topical
Use this medication on the skin only. However, do not use it on the face, groin, or underarms unless directed to do so by your doctor.
Wash and dry your hands before using. Clean and dry the affected area. Apply a thin film of medication to the affected area and gently rub in, usually 1-3 times daily or as directed by your doctor. Do not bandage, cover, or wrap the area unless directed to do so by your doctor. If used in the diaper area on an infant, do not use tight-fitting diapers or plastic pants.
After applying the medication, wash your hands unless you are using this medication to treat the hands. When applying this medication near the eyes, avoid getting it in the eyes because this may worsen or cause glaucoma. Also, avoid getting this medication in the nose or mouth. If you get the medication in these areas, rinse with plenty of water.
Use this medication only for the condition for which it was prescribed. Do not use it for longer than prescribed.
Inform your doctor if your condition persists or worsens after 2 weeks.
Betamethasone valerate description
Betamethasone valerate Cream: Betamethasone valerate contains Betamethasone valerate 0.1% as 17-valerate in a water-miscible base.
It also contains the following excipients: Chlorocresol, macrogol cetostearyl ether, cetostearyl alcohol, white soft paraffin, liquid paraffin, sodium acid phosphate, phosphoric acid, sodium hydroxide and purified water.
Betamethasone valerate RD Cream: Betamethasone valerate RD Cream contains Betamethasone valerate 0.025% as the valerate ester in a water-miscible base.
It also contains the following excipients: Cetostearyl alcohol, macrogol cetostearyl ether, white soft paraffin, liquid paraffin, chlorocresol, anhydrous disodium hydrogen phosphate, citric acid monohydrate and purified water.
Betamethasone valerate Scalp Application: Betamethasone valerate Scalp Application contains Betamethasone valerate 0.1% w/w as valerate. The vehicle contains 50% of isopropyl alcohol, which has antibacterial activity. This preparation complies with the specifications for Betamethasone valerate Valerate Scalp Application BP.
It also contains the following excipients: Carbomer, isopropyl alcohol, sodium hydroxide and purified water.
Betamethasone valerate dosage
Note: For proper dispensing of foam, can must be inverted.
For application to the scalp invert can and dispense a small amount of Betamethasone valerate Valerate Foam, 0.12% onto a saucer or other cool surface. Do not dispense directly onto hands as foam will begin to melt immediately upon contact with warm skin. Pick up small amounts of foam with fingers and gently massage into affected area until foam disappears. Repeat until entire affected scalp area is treated. Apply twice daily, once in the morning and once at night.
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
Betamethasone valerate Valerate Foam, 0.12% should not be used with occlusive dressings unless directed by a physician.
Betamethasone valerate interactions
See also:
What other drugs will affect Betamethasone valerate?
Concurrent use of barbiturates, carbamazepine, phenytoin, primidone or rifampicin may enhance the metabolism and reduce the effects of systemic corticosteroids. Conversely, oral contraceptives or ritonavir may increase plasma concentrations of corticosteroids.
Use of corticosteroids with potassium-depleting diuretics eg, thiazides or furosemide may cause excessive potassium loss. There is also an increased risk of hypokalemia with concurrent amphotericin B or bronchodilator therapy with xanthines or β2 agonist.
There may be an increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs. Corticosteroids may alter response to anticoagulants increasing requirements of antidiabetic drugs and antihypertensives.
Corticosteroids may decrease serum concentrations of salicylates and may decrease the effect of antimuscarinics in myasthenia gravis.
Betamethasone valerate side effects
See also:
What are the possible side effects of Betamethasone valerate?
The most frequent adverse event was burning/itching/ stinging at the application site; the incidence and severity of this event were as follows:
| Incidence and severity of burning/itching/stinging | ||||
| Product | Total incidence | Maximum severity | ||
| Mild | Moderate | Severe | ||
| Betamethasone valerate Valerate Foam, 0.12% n=63 | 34 (54%) | 28 (44%) | 5 (8%) | 1 (2%) |
| Betamethasone valerate Valerate Lotion n=63 | 33 (52%) | 26 (41%) | 6 (10%) | 1 (2%) |
| Placebo Foam n=32 | 24 (75%) | 13 (41%) | 7 (22%) | 4 (12%) |
| Placebo Lotion n=30 | 20 (67%) | 12 (40%) | 5 (17%) | 3 (10%) |
Other adverse events which were considered to be possibly, probably, or definitely related to Betamethasone valerate Valerate Foam, 0.12% occurred in one patient each; these were paresthesia, pruritus, acne, alopecia, and conjunctivitis.
The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximately decreasing order of occurrence: irritation, dryness, folliculitis, acneiform eruptions hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Betamethasone valerate contraindications
See also:
What is the most important information I should know about Betamethasone valerate?
Hypersensitivity to Betamethasone valerate valerate or to any of the ingredients of Betamethasone valerate Cream/Betamethasone valerate RD Cream/Betamethasone valerate Scalp Application.
Betamethasone valerate valerate is contraindicated in dermatoses in infants <1 year, including dermatitis.
Betamethasone valerate Cream/Betamethasone valerate RD Cream: Rosacea; acne vulgaris; perioral dermatitis; perianal and genital pruritus; pruritus without inflammation; primary cutaneous viral infections (eg, herpes simplex, chickenpox).
The use of Betamethasone valerate Cream/Betamethasone valerate RD Cream is not indicated in the treatment of primarily infected skin lesions caused by infection with fungi or bacteria.
Betamethasone valerate Scalp Application: Infections of the scalp.
Active ingredient matches for Betamethasone sodium phosphate/Betamethasone valerate:
Betamethasone sodium phosphate/Betamethasone valerate
References
- DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "betamethasone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "betamethasone". http://www.drugbank.ca/drugs/DB00443 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Betamethasone sodium phosphate/Betamethasone valerate are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Betamethasone sodium phosphate/Betamethasone valerate. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
